|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:ATCCode
|
gptkb:J01FA01
|
|
gptkbp:availableOn
|
gptkb:hospital
gptkb:tablet
capsule
suspension
injection
|
|
gptkbp:bioavailability
|
variable
|
|
gptkbp:brand
|
gptkb:Erymax
gptkb:Erythrocin
gptkb:Ilosone
Erythroped
|
|
gptkbp:CASNumber
|
114-07-8
|
|
gptkbp:contraindication
|
gptkb:liver_disease
hypersensitivity to macrolides
|
|
gptkbp:discoveredBy
|
gptkb:J._M._McGuire
|
|
gptkbp:discoveredIn
|
1952
|
|
gptkbp:drugClass
|
macrolide
|
|
gptkbp:eliminationHalfLife
|
1.5 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:hasMolecularFormula
|
C37H67NO13
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
erythromycin
|
|
gptkbp:interactsWith
|
gptkb:cyclosporine
gptkb:phenytoin
gptkb:theophylline
gptkb:warfarin
gptkb:pimozide
gptkb:carbamazepine
gptkb:cisapride
gptkb:ergotamine
gptkb:digoxin
gptkb:dihydroergotamine
statins
colchicine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1952
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
733.93 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:producedBy
|
gptkb:Saccharopolyspora_erythraea
|
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
QT prolongation
liver toxicity
|
|
gptkbp:target
|
50S ribosomal subunit
|
|
gptkbp:usedFor
|
gptkb:legionnaires'_disease
diphtheria
skin infections
syphilis
acne
bacterial infections
respiratory tract infections
pertussis
chlamydia infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Macrolides
gptkb:CYP3_family
gptkb:CYP3A4
gptkb:Tegretol
gptkb:Streptococcus
gptkb:Imodium
|
|
gptkbp:bfsLayer
|
5
|